|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM379599392 |
| 003 |
DE-627 |
| 005 |
20241212232514.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
241031s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202409102
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1629.xml
|
| 035 |
|
|
|a (DE-627)NLM379599392
|
| 035 |
|
|
|a (NLM)39473316
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Qi, Lin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Omics-Enhanced Nanomedicine for Cancer Therapy
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 12.12.2024
|
| 500 |
|
|
|a Date Revised 12.12.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2024 Wiley‐VCH GmbH.
|
| 520 |
|
|
|a Cancer nanomedicine has emerged as a promising approach to overcome the limitations of conventional cancer therapies, offering enhanced efficacy and safety in cancer management. However, the inherent heterogeneity of tumors presents increasing challenges for the application of cancer nanomedicine in both diagnosis and treatment. This heterogeneity necessitates the integration of advanced and high-throughput analytical techniques to tailor nanomedicine strategies to individual tumor profiles. Omics technologies, encompassing genomics, epigenomics, transcriptomics, proteomics, metabolomics, and more, provide unparalleled insights into the molecular and cellular mechanisms underlying cancer. By dissecting tumor heterogeneity across multiple levels, these technologies offer robust support for the development of personalized and precise cancer nanomedicine strategies. In this review, the principles, techniques, and applications of key omics technologies are summarized. Especially, the synergistic integration of omics and nanomedicine in cancer therapy is explored, focusing on enhanced diagnostic accuracy, optimized therapeutic strategies and the assessment of nanomedicine-mediated biological responses. Moreover, this review addresses current challenges and outlines future directions in the field of omics-enhanced nanomedicine. By offering valuable insights and guidance, this review aims to advance the integration of omics with nanomedicine, ultimately driving improved diagnostic and therapeutic strategies for cancer
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a cancer therapy
|
| 650 |
|
4 |
|a nanomedicine
|
| 650 |
|
4 |
|a nanomedicine‐mediated biological response
|
| 650 |
|
4 |
|a nanosystem design
|
| 650 |
|
4 |
|a omics technology
|
| 700 |
1 |
|
|a Li, Zhihong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liu, Jianping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Xiaoyuan
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 36(2024), 50 vom: 01. Dez., Seite e2409102
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:36
|g year:2024
|g number:50
|g day:01
|g month:12
|g pages:e2409102
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202409102
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 36
|j 2024
|e 50
|b 01
|c 12
|h e2409102
|